Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 ...
SAN FRANCISCO -- First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant metastatic colorectal cancer (mCRC), according to the ...
Pfizer PFE announced positive top-line results from the progression-free survival (PFS) analysis of a late-stage study of its oncology drug, Braftovi (encorafenib), for treating patients with ...
In patients with BRAF V600E-mutant metastatic colorectal cancer, a combination of encorafenib, cetuximab, and mFOLFOX6 chemotherapy showed a 60.9% overall response rate, outperforming the 40% ...
"These data from the BREAKWATER study show the potential for this targeted treatment regimen to become the new standard of care for people with BRAF V600E-mutant metastatic colorectal cancer ...
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed ...
恩考拉非尼、西妥昔单抗和 mFOLFOX6 的组合疗法已获得 FDA 的加速批准，用于治疗患有 BRAF V600E 突变的转移性结直肠癌患者。 美国食品药品监督管理局（FDA）加速批准恩科拉非尼（Braftovi，辉瑞公司子公司 Array ...
Pfizer’s metastatic colorectal cancer (mCRC) combination therapy has met one of the primary endpoints of improving progression-free survival (PFS) in a Phase III trial, further supporting a full ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN ...
Braftovi was a combination with Lilly’s Erbitux for adults with mCRC with a BRAF V600E mutation after prior therapy. The BREAKWATER study data is being reviewed by global regulatory authorities ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback